Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Current Assets for 12 consecutive years, with $122.0 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 34.08% year-over-year to $122.0 million; the TTM value through Mar 2026 reached $122.0 million, down 34.08%, while the annual FY2025 figure was $129.3 million, 40.32% down from the prior year.
  • Current Assets hit $122.0 million in Q1 2026 for Cartesian Therapeutics, down from $129.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $229.1 million in Q3 2024 and bottomed at $89.9 million in Q3 2023.
  • Average Current Assets over 5 years is $145.9 million, with a median of $138.4 million recorded in 2023.
  • Year-over-year, Current Assets crashed 43.72% in 2023 and then soared 154.97% in 2024.
  • Cartesian Therapeutics' Current Assets stood at $148.1 million in 2022, then crashed by 38.75% to $90.7 million in 2023, then skyrocketed by 138.76% to $216.6 million in 2024, then crashed by 40.32% to $129.3 million in 2025, then fell by 5.6% to $122.0 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $122.0 million, $129.3 million, and $147.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.